References
- Patel RV, Clark LN, Lebowl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001–1017.
- Stern RS, Leibman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst. 1998;90:1278–1284.
- Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow up Study. Cancer. 1994;73:2759–2764.
- Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: Nested cohort cross-over study. Lancet. 2001;358:1042–1045.
- Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol. 2003;120:211–216.
- Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, A review of malignancies during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204–214.
- Chakravarty EF, MIchaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130–2135.
- Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology. 2007;46:1623–1624.
- Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50:S75–S77.
- Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953–956.
- Fryrear RS 2nd, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol. 2004;51:1026.
- Williams GM. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur J Cancer Prev. 2008;17:169–177.
- Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, An anti-tumor necrosis factor-alfa antibody inhibits the development of experimental skin tumors. Mol Cancer Ther. 2003;2:445–451.
- National Institute for Clinical Excellence (NICE) Guidelines, TA104 Psoriatic arthritis, etanercept and infliximab–guidance, July 2006; and NICE Guidelines, TA103 Psoriasis, efalizumab and etanercept–guidance, July 2006.
- Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1–70.